An interventional study of Control IQ + sleep or exercise activity with TI in Diabetes Mellitus, Type 1, sponsored by Jaeb Center for Health Research. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Jaeb Center for Health Research · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research — 1 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Jaeb Center for Health Research.
Among the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, this one is the 23rd largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 35th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research is open now, in 1 country.
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 7 · Phase 4 5
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 74 across the 29 interventional studies, 77 across the 7 observational. Of the 34 that completed or were terminated, 20 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
1 of the studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06959316Jaeb Center for Health ResearchT1D Pregnancy & Me | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.
The study is a 3-period randomized crossover trial, each with a structured afternoon exercise session following a standard lunch meal.
9 participants completed Phase 1 sessions which included (1) TI for meal bolus with pump in sleep mode, (2) RAA for meal bolus with pump in sleep mode, and (3) RAA for meal bolus with pump in standard mode with transition to exercise mode one hour before start of exercise.
21 participants will complete the Phase 2 sessions which will include: (1) TI for meal bolus with pump in exercies mode, (2) TI for meal air bolus (i.e., the infusion set is disconnected from the pump and the TI bolus and carbohydrates are reported in the system but no pump insulin is administered) with pump in exercise mode, and (3) RAA for meal bolus with pump in exercise mode.
The study is being done to compare the efficacy and safety of TI versus RAA given as bolus for meal prior to initiating aerobic exercise in adults ≥18 to ≤ 65 years of age with T1D using Control-IQ.
All participants will complete 3 exercise sessions, with the order determined through randomization. Participants who complete Phase 1 may also participate in Phase 2 if they choose to.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnant or lactating, planning to become pregnant during the study, or is of and not on acceptable form of (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months )
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PHASE 1: TI for meal bolus with Control IQ + sleep activity pump setting. PHASE 2: TI for meal bolus with Control IQ+ exercise activity pump setting.
Device: Control IQ + sleep or exercise activity with TI
PHASE 1: RAA for meal bolus with the Control IQ + sleep activity pump setting. PHASE 2: RAA for meal bolus with Control IQ + exercise activity pump setting.
PHASE 1: RAA for meal bolus with Control IQ pump setting with transition to Control IQ + exercise activity pump setting one hour before start of exercise. PHASE 2: TI for meal air bolus where the infusion set is disconnected and the bolus is entered into the pump with meal carbohydrates (no subcutaneous insulin is delivered from the pump), with Control IQ + exercise activity pump setting
PHASE 1: TI for meal bolus with Control IQ + sleep activity pump setting PHASE 2: TI for meal bolus with Control IQ + exercise activity pump setting
PHASE 1: Blood glucose <70 mg/dL
Blood glucose \<70 mg/dL within 90 minutes from the start of exercise
Time frame: 90 minutes
PHASE 2: Blood glucose <70 mg/dL
Blood glucose \<70 mg/dL within 90 minutes from the start of exercise
Time frame: 90 minutes
PHASE 1: Exploratory Efficacy Outcome: Change in blood glucose from exercise start to nadir glucose
Change in blood glucose from exercise start to nadir glucose within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 1: Exploratory Efficacy Outcome: Change in CGM glucose from exercise start to nadir glucose
Change in CGM glucose from exercise start to nadir glucose within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 1: Exploratory Efficacy Outcome: Time in range 70-180 mg/dL
Time in range 70-180 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 1: Exploratory Efficacy Outcome: Time in tight range 70-140 mg/dL
Time in tight range 70-140 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 1: Exploratory Efficacy Outcome: Mean glucose
Mean glucose within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 1: Exploratory Efficacy Outcome: CGM glucose <54 mg/dL
CGM glucose \<54 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 1: Exploratory Efficacy Outcome: CGM glucose <70 mg/dL
CGM glucose \<70 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 1: Exploratory Efficacy Outcome: CGM glucose >250 mg/dL
CGM glucose \>250 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 1: Exploratory Efficacy Outcome: CGM glucose >300 mg/dL
CGM glucose \>300 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 1: Safety Outcome: Severe hypoglycemia events
Defined as events requiring assistance of another person due to cognitive impairment to actively administer carbohydrate, glucagon, or other resuscitative actions
Time frame: From enrollment to last clinic visit (up to ~12 weeks)
PHASE 1: Safety Outcome: Blood glucose <54 mg/dL during clinic
Blood glucose \<54 mg/dL between start of meal and discharge from clinic
Time frame: 210 minutes
PHASE 1: Safety Outcome: Blood glucose <70 mg/dL during clinic
Blood glucose \<70 mg/dL between start of meal and discharge from clinic
Time frame: 210 minutes
PHASE 1: Safety Outcome: Adverse events related to exercise procedure
Adverse events related to the exercise procedure
Time frame: From enrollment to last clinic visit (up to ~12 weeks)
PHASE 1: Safety Outcome: Adverse events associated with technosphere insulin inhalation
Adverse events associated with technosphere insulin (TI) inhalation: hypersensitivity reaction, acute bronchospasm, treatment provided for asthma symptoms, or other symptoms associated with TI dosing
Time frame: From enrollment to last clinic visit (up to ~12 weeks)
PHASE 2: Exploratory Efficacy Outcome: Change in blood glucose from exercise start to nadir glucose
Change in blood glucose from exercise start to nadir glucose within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 2: Exploratory Efficacy Outcome: Change in CGM glucose from exercise start to nadir glucose
Change in CGM glucose from exercise start to nadir glucose within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 2: Exploratory Efficacy Outcome: Time in range 70-180 mg/dL
Time in range 70-180 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 2: Exploratory Efficacy Outcome: Time in tight range 70-140 mg/dL
Time in tight range 70-140 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 2: Exploratory Efficacy Outcome: Mean glucose
Mean glucose within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 2: Exploratory Efficacy Outcome: CGM glucose <54 mg/dL
CGM glucose \<54 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 2: Exploratory Efficacy Outcome: CGM glucose <70 mg/dL
CGM glucose \<70 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 2: Exploratory Efficacy Outcome: CGM glucose >250 mg/dL
CGM glucose \>250 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 2: Exploratory Efficacy Outcome: CGM glucose >300 mg/dL
CGM glucose \>300 mg/dL within 90 minutes from start of exercise
Time frame: 90 minutes
PHASE 2: Safety Outcome: Severe hypoglycemia events
Defined as events requiring assistance of another person due to cognitive impairment to actively administer carbohydrate, glucagon, or other resuscitative actions
Time frame: From enrollment to last clinic visit (up to ~12 weeks)
PHASE 2: Safety Outcome: Blood glucose <54 mg/dL during clinic
Blood glucose \<54 mg/dL between start of meal and discharge from clinic
Time frame: 210 minutes
PHASE 2: Safety Outcome: Blood glucose <70 mg/dL during clinic
Blood glucose \<70 mg/dL between start of meal and discharge from clinic
Time frame: 210 minutes
PHASE 2: Safety Outcome: Adverse events related to exercise procedure
Adverse events related to the exercise procedure
Time frame: From enrollment to last clinic visit (up to ~12 weeks)
PHASE 2: Safety Outcome: Adverse events associated with technosphere insulin inhalation
Adverse events associated with technosphere insulin (TI) inhalation: hypersensitivity reaction, acute bronchospasm, treatment provided for asthma symptoms, or other symptoms associated with TI dosing
Time frame: From enrollment to last clinic visit (up to ~12 weeks)
Plan to share: Undecided — A limited dataset is expected to be made available.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 16 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jaeb Center for Health Research →